Testicular cancer survivorship

Research strategies and recommendations

Lois B. Travis, Clair Beard, James M. Allan, Alv A. Dahl, Darren R. Feldman, Jan Oldenburg, Gedske Daugaard, Jennifer L. Kelly, M. Eileen Dolan, Robyn Hannigan, Louis S. Constine, Kevin C. Oeffinger, Paul Okunieff, Gregory Armstrong, David Wiljer, Robert C. Miller, Jourik A. Gietema, Flora E. Van Leeuwen, Jacqueline P. Williams, Craig R. Nichols & 2 others Lawrence H. Einhorn, Sophie D. Fossa

Research output: Contribution to journalComment/debate

172 Citations (Scopus)

Abstract

Testicular cancer represents the most curable solid tumor, with a 10-year survival rate of more than 95%. Given the young average age at diagnosis, it is estimated that effective treatment approaches, in particular, platinum-based chemotherapy, have resulted in an average gain of several decades of life. This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, decreased fertility, and psychosocial problems. Data on underlying genetic or molecular factors that might identify those patients at highest risk for late sequelae are sparse. Genome-wide association studies and other translational molecular approaches now provide opportunities to identify testicular cancer survivors at greatest risk for therapy-related complications to develop evidence-based long-term follow-up guidelines and interventional strategies. We review research priorities identified during an international workshop devoted to testicular cancer survivors. Recommendations include 1) institution of lifelong follow-up of testicular cancer survivors within a large cohort setting to ascertain risks of emerging toxicities and the evolution of known late sequelae, 2) development of comprehensive risk prediction models that include treatment factors and genetic modifiers of late sequelae, 3) elucidation of the effect(s) of decades-long exposure to low serum levels of platinum, 4) assessment of the overall burden of medical and psychosocial morbidity, and 5) the eventual formulation of evidence-based long-term follow-up guidelines and interventions. Just as testicular cancer once served as the paradigm of a curable malignancy, comprehensive follow-up studies of testicular cancer survivors can pioneer new methodologies in survivorship research for all adult-onset cancer.

Original languageEnglish (US)
Pages (from-to)1114-1130
Number of pages17
JournalJournal of the National Cancer Institute
Volume102
Issue number15
DOIs
StatePublished - Aug 4 2010
Externally publishedYes

Fingerprint

Testicular Neoplasms
Survival Rate
Survivors
Research
Platinum
Guidelines
Morbidity
Neoplasms
Hypogonadism
Second Primary Neoplasms
Genome-Wide Association Study
Fertility
Molecular Biology
Cardiovascular Diseases
Therapeutics
Education
Drug Therapy
Lung
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Travis, L. B., Beard, C., Allan, J. M., Dahl, A. A., Feldman, D. R., Oldenburg, J., ... Fossa, S. D. (2010). Testicular cancer survivorship: Research strategies and recommendations. Journal of the National Cancer Institute, 102(15), 1114-1130. https://doi.org/10.1093/jnci/djq216

Testicular cancer survivorship : Research strategies and recommendations. / Travis, Lois B.; Beard, Clair; Allan, James M.; Dahl, Alv A.; Feldman, Darren R.; Oldenburg, Jan; Daugaard, Gedske; Kelly, Jennifer L.; Dolan, M. Eileen; Hannigan, Robyn; Constine, Louis S.; Oeffinger, Kevin C.; Okunieff, Paul; Armstrong, Gregory; Wiljer, David; Miller, Robert C.; Gietema, Jourik A.; Van Leeuwen, Flora E.; Williams, Jacqueline P.; Nichols, Craig R.; Einhorn, Lawrence H.; Fossa, Sophie D.

In: Journal of the National Cancer Institute, Vol. 102, No. 15, 04.08.2010, p. 1114-1130.

Research output: Contribution to journalComment/debate

Travis, LB, Beard, C, Allan, JM, Dahl, AA, Feldman, DR, Oldenburg, J, Daugaard, G, Kelly, JL, Dolan, ME, Hannigan, R, Constine, LS, Oeffinger, KC, Okunieff, P, Armstrong, G, Wiljer, D, Miller, RC, Gietema, JA, Van Leeuwen, FE, Williams, JP, Nichols, CR, Einhorn, LH & Fossa, SD 2010, 'Testicular cancer survivorship: Research strategies and recommendations', Journal of the National Cancer Institute, vol. 102, no. 15, pp. 1114-1130. https://doi.org/10.1093/jnci/djq216
Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J et al. Testicular cancer survivorship: Research strategies and recommendations. Journal of the National Cancer Institute. 2010 Aug 4;102(15):1114-1130. https://doi.org/10.1093/jnci/djq216
Travis, Lois B. ; Beard, Clair ; Allan, James M. ; Dahl, Alv A. ; Feldman, Darren R. ; Oldenburg, Jan ; Daugaard, Gedske ; Kelly, Jennifer L. ; Dolan, M. Eileen ; Hannigan, Robyn ; Constine, Louis S. ; Oeffinger, Kevin C. ; Okunieff, Paul ; Armstrong, Gregory ; Wiljer, David ; Miller, Robert C. ; Gietema, Jourik A. ; Van Leeuwen, Flora E. ; Williams, Jacqueline P. ; Nichols, Craig R. ; Einhorn, Lawrence H. ; Fossa, Sophie D. / Testicular cancer survivorship : Research strategies and recommendations. In: Journal of the National Cancer Institute. 2010 ; Vol. 102, No. 15. pp. 1114-1130.
@article{5c55530261604ed5b99af16aa6e422ed,
title = "Testicular cancer survivorship: Research strategies and recommendations",
abstract = "Testicular cancer represents the most curable solid tumor, with a 10-year survival rate of more than 95{\%}. Given the young average age at diagnosis, it is estimated that effective treatment approaches, in particular, platinum-based chemotherapy, have resulted in an average gain of several decades of life. This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, decreased fertility, and psychosocial problems. Data on underlying genetic or molecular factors that might identify those patients at highest risk for late sequelae are sparse. Genome-wide association studies and other translational molecular approaches now provide opportunities to identify testicular cancer survivors at greatest risk for therapy-related complications to develop evidence-based long-term follow-up guidelines and interventional strategies. We review research priorities identified during an international workshop devoted to testicular cancer survivors. Recommendations include 1) institution of lifelong follow-up of testicular cancer survivors within a large cohort setting to ascertain risks of emerging toxicities and the evolution of known late sequelae, 2) development of comprehensive risk prediction models that include treatment factors and genetic modifiers of late sequelae, 3) elucidation of the effect(s) of decades-long exposure to low serum levels of platinum, 4) assessment of the overall burden of medical and psychosocial morbidity, and 5) the eventual formulation of evidence-based long-term follow-up guidelines and interventions. Just as testicular cancer once served as the paradigm of a curable malignancy, comprehensive follow-up studies of testicular cancer survivors can pioneer new methodologies in survivorship research for all adult-onset cancer.",
author = "Travis, {Lois B.} and Clair Beard and Allan, {James M.} and Dahl, {Alv A.} and Feldman, {Darren R.} and Jan Oldenburg and Gedske Daugaard and Kelly, {Jennifer L.} and Dolan, {M. Eileen} and Robyn Hannigan and Constine, {Louis S.} and Oeffinger, {Kevin C.} and Paul Okunieff and Gregory Armstrong and David Wiljer and Miller, {Robert C.} and Gietema, {Jourik A.} and {Van Leeuwen}, {Flora E.} and Williams, {Jacqueline P.} and Nichols, {Craig R.} and Einhorn, {Lawrence H.} and Fossa, {Sophie D.}",
year = "2010",
month = "8",
day = "4",
doi = "10.1093/jnci/djq216",
language = "English (US)",
volume = "102",
pages = "1114--1130",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Testicular cancer survivorship

T2 - Research strategies and recommendations

AU - Travis, Lois B.

AU - Beard, Clair

AU - Allan, James M.

AU - Dahl, Alv A.

AU - Feldman, Darren R.

AU - Oldenburg, Jan

AU - Daugaard, Gedske

AU - Kelly, Jennifer L.

AU - Dolan, M. Eileen

AU - Hannigan, Robyn

AU - Constine, Louis S.

AU - Oeffinger, Kevin C.

AU - Okunieff, Paul

AU - Armstrong, Gregory

AU - Wiljer, David

AU - Miller, Robert C.

AU - Gietema, Jourik A.

AU - Van Leeuwen, Flora E.

AU - Williams, Jacqueline P.

AU - Nichols, Craig R.

AU - Einhorn, Lawrence H.

AU - Fossa, Sophie D.

PY - 2010/8/4

Y1 - 2010/8/4

N2 - Testicular cancer represents the most curable solid tumor, with a 10-year survival rate of more than 95%. Given the young average age at diagnosis, it is estimated that effective treatment approaches, in particular, platinum-based chemotherapy, have resulted in an average gain of several decades of life. This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, decreased fertility, and psychosocial problems. Data on underlying genetic or molecular factors that might identify those patients at highest risk for late sequelae are sparse. Genome-wide association studies and other translational molecular approaches now provide opportunities to identify testicular cancer survivors at greatest risk for therapy-related complications to develop evidence-based long-term follow-up guidelines and interventional strategies. We review research priorities identified during an international workshop devoted to testicular cancer survivors. Recommendations include 1) institution of lifelong follow-up of testicular cancer survivors within a large cohort setting to ascertain risks of emerging toxicities and the evolution of known late sequelae, 2) development of comprehensive risk prediction models that include treatment factors and genetic modifiers of late sequelae, 3) elucidation of the effect(s) of decades-long exposure to low serum levels of platinum, 4) assessment of the overall burden of medical and psychosocial morbidity, and 5) the eventual formulation of evidence-based long-term follow-up guidelines and interventions. Just as testicular cancer once served as the paradigm of a curable malignancy, comprehensive follow-up studies of testicular cancer survivors can pioneer new methodologies in survivorship research for all adult-onset cancer.

AB - Testicular cancer represents the most curable solid tumor, with a 10-year survival rate of more than 95%. Given the young average age at diagnosis, it is estimated that effective treatment approaches, in particular, platinum-based chemotherapy, have resulted in an average gain of several decades of life. This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, decreased fertility, and psychosocial problems. Data on underlying genetic or molecular factors that might identify those patients at highest risk for late sequelae are sparse. Genome-wide association studies and other translational molecular approaches now provide opportunities to identify testicular cancer survivors at greatest risk for therapy-related complications to develop evidence-based long-term follow-up guidelines and interventional strategies. We review research priorities identified during an international workshop devoted to testicular cancer survivors. Recommendations include 1) institution of lifelong follow-up of testicular cancer survivors within a large cohort setting to ascertain risks of emerging toxicities and the evolution of known late sequelae, 2) development of comprehensive risk prediction models that include treatment factors and genetic modifiers of late sequelae, 3) elucidation of the effect(s) of decades-long exposure to low serum levels of platinum, 4) assessment of the overall burden of medical and psychosocial morbidity, and 5) the eventual formulation of evidence-based long-term follow-up guidelines and interventions. Just as testicular cancer once served as the paradigm of a curable malignancy, comprehensive follow-up studies of testicular cancer survivors can pioneer new methodologies in survivorship research for all adult-onset cancer.

UR - http://www.scopus.com/inward/record.url?scp=77955459338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955459338&partnerID=8YFLogxK

U2 - 10.1093/jnci/djq216

DO - 10.1093/jnci/djq216

M3 - Comment/debate

VL - 102

SP - 1114

EP - 1130

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 15

ER -